Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience
Claudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
Journal of Neurology (2022) Vol. 269, Iss. 11, pp. 5848-5857
Open Access | Times Cited: 25

Showing 25 citing articles:

Risk factors for migraine disease progression: a narrative review for a patient-centered approach
Richard B. Lipton, Dawn C. Buse, Stephanie J. Nahas, et al.
Journal of Neurology (2023) Vol. 270, Iss. 12, pp. 5692-5710
Open Access | Times Cited: 45
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 37
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 5, pp. 1435-1442
Closed Access | Times Cited: 17
Real-world effectiveness of erenumab in Japanese patients with migraine
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Heliyon (2024) Vol. 10, Iss. 4, pp. e26568-e26568
Open Access | Times Cited: 5
Switching between anti-cgrp monoclonal antibodies in migraine prophylaxis
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
Hans-Christoph Diener, Kathleen A. Day, Sarah Lipsius, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
Nicolas Vandenbussche, Karolina Pisarek, Koen Paemeleire
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 12
Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
Laura Pilati, A de Torrenté, Salvatore Di Marco, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3585-3585
Open Access | Times Cited: 10
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 948-948
Open Access | Times Cited: 3
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
Francesca Schiano di Cola, Marco Bolchini, Salvatore Caratozzolo, et al.
Neurology International (2023) Vol. 15, Iss. 1, pp. 273-284
Open Access | Times Cited: 8
Reversion of chronic to episodic migraine in working age and botulinum toxin‐resistant patients treated with fremanezumab: A real‐life study
Juan Tudela‐Tomas, Rosa‐Maria Ramos‐Guerrero, Maria‐Eugenia Rodriguez‐Mateos
Brain and Behavior (2024) Vol. 14, Iss. 7
Open Access | Times Cited: 2
Cgrp Monoclonal Antibodies: Key Lessons from Real World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
(2024)
Open Access | Times Cited: 2
OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study
Claudia Altamura, Raffaele Ornello, Fayyaz Ahmed, et al.
Journal of Neurology (2022) Vol. 270, Iss. 2, pp. 986-994
Closed Access | Times Cited: 9
Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
Claudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 959-971
Open Access | Times Cited: 4
Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)
Fabrizio Vernieri, Luigi Francesco Iannone, Simona Guerzoni, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 2, pp. 415-435
Open Access | Times Cited: 1
Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review
Patricia Pozo‐Rosich, David García‐Azorín, Silvia Díaz‐Cerezo, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 1
Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review
Délia Szok, Anett Csáti, László Vécsei, et al.
Life (2023) Vol. 13, Iss. 3, pp. 665-665
Open Access | Times Cited: 2
Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies
Vinícius Lins Ferreira, Felipe F. Mainka, Astrid Wiens, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 9, pp. 669-680
Closed Access | Times Cited: 2
Clinical Management of Migraine
Maria Albanese
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 5225-5225
Open Access | Times Cited: 3
Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
Shuu‐Jiun Wang, Byung‐Kun Kim, Hebo Wang, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 143-152
Closed Access
(CGRP) Monocloncal antibodies
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
Migraine treatment with biological therapies. The state of the art
Abouch Valenty Krymchantowski, Carla Jevoux, Raimundo Pereira Silva‐Néto
Deleted Journal (2023) Vol. 14, Iss. 3, pp. 144-152
Open Access | Times Cited: 1
Galcanezumab in the Treatment of Migraine: A Narrative Review of Real-World Studies
G Agnello, Carlotta Buzzoni, Amalia Antenori, et al.
Clinical Neuropharmacology (2023) Vol. 46, Iss. 6, pp. 220-228
Closed Access | Times Cited: 1
Galcanezumab for the preventive treatment of episodic and chronic migraine in real life: A prospective multicenter study in Colombia and Mexico including effects on anxiety and depression - On behalf of ASOLACE
Joe Fernando Muñoz-Cerón, Karina Vélez-Jiménez, Stephanía Bohorquez-Valderrama, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
Page 1

Scroll to top